Cajal Neuroscience

Cajal Neuroscience

Edit info

  • Founded: 2020
  • Location: Seattle, WA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: neurodegenerative
  • Drug types: NEU
  • Lead product: Undisclosed
  • Funding: $96M A Nov 2022
  • Investors: The Column Group, Lux Capital, Two Sigma Ventures, Evotec, Bristol Myers Squibb, Alexandria Venture Investments, Dolby Family Ventures


cajalneuro.com

linkedin.com

job board


Business:

Neurodegenerative Therapies

Drug notes:

Undisclosed RD Parkinson's disease

About:

Cajal Neuroscience is developing drugs for neurodegenerative diseases. The complexity of the brain was uncovered by pioneering research by Santiago Ramón y Cajal, who illustrated his findings with hundreds of drawings. Inspired by his creativity, Cajal Neuroscience is researching how to model and treat complex diseases of the brain. By using a combination of high throughput microscopy, functional genetic screening and multi-omics approaches, Cajal can identify new drug targets for neurodegenerative diseases. To achieve success, Cajal will employ expertise from neurosurgeons, scientists and software engineers to generate and analyze high quality data.

Cajal Neuroscience
Sr. Manager, Finance & Accounting
Seattle, WA|57 days ago
Apply


© 2025 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com